Charles River Laboratories hits 52-week high amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 06 Jan 26
Source: NASDAQ.COM
Charles River Laboratories International Inc (CRL) experienced a price increase of 3.73%, reaching a 52-week high. This upward movement aligns with the broader market context, as the Nasdaq-100 rose by 0.89% and the S&P 500 gained 0.65%.
The stock's performance is attributed to sector rotation, as investors are increasingly focusing on companies within the life sciences sector, reflecting a shift in market sentiment towards healthcare and biotech firms. This trend is further supported by the overall positive market conditions.
The implications of this price movement suggest that CRL is well-positioned to capitalize on the growing interest in life sciences, potentially leading to further gains as investor confidence in the sector strengthens.
Analyst Views on CRL
Wall Street analysts forecast CRL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 202.10 USD with a low forecast of 170.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
8 Buy
4 Hold
0 Sell
Moderate Buy
Current: 216.880
Low
170.00
Averages
202.10
High
225.00
Current: 216.880
Low
170.00
Averages
202.10
High
225.00
About CRL
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
